{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:00:35Z","timestamp":1790834435719,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY23H090014"],"award-info":[{"award-number":["LTGY23H090014"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pregabalin is widely used in the management of neuropathic pain and generalized anxiety disorder. However, comprehensive real-world evidence regarding its neuropsychiatric safety profile and age-specific risk variations remains insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrieved from the FDA Adverse Event Reporting System (FAERS) from Q1 2005 to Q1 2025. Four disproportionality algorithms\u2014reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM)\u2014were utilized to identify safety signals. The Weibull distribution model characterized the time-to-onset (TTO) of adverse events (AEs) and compared risks across age subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After analyzing 98,196 pregabalin-related reports, 279 preferred terms generated consistent signals using all four disproportionality methods. Confirmed AEs included dizziness, weight increased, and somnolence. Unexpected signals were identified, such as hypoacusis, dysgraphia, logorrhoea, and feeling of despair. Age-stratified analysis revealed that older adults (\u226565 years) showed higher risks for falls, and balance disorder. In contrast, adults (18\u201364.9 years) more frequently reported withdrawal syndrome, drug dependence, and suicidal ideation. The TTO analysis revealed that 54.53% of AEs emerged during the initial month of treatment. The median onset was shorter in older adults (16 days) than in adults (30 days). The Weibull shape parameters (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      ) for both groups were below 1 (0.46 and 0.48, respectively), indicating an early failure type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies novel safety signals and distinct age-related risk patterns. Vigilant monitoring during the initial treatment phase is essential, particularly for neuropsychiatric stability and physical safety in vulnerable populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1806099","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:40:09Z","timestamp":1790833209000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-stratified signals and early onset of adverse events with pregabalin: a disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianghai","family":"He","sequence":"first","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesong","family":"Pan","sequence":"additional","affiliation":[{"name":"Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People\u2019s Hospital","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixiang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Postgraduate Training base Alliance of Wenzhou Medical University (Wenzhou People\u2019s Hospital)","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangting","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People\u2019s Hospital","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yao","sequence":"additional","affiliation":[{"name":"Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People\u2019s Hospital","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s12035-024-04424-w","article-title":"The voltage-gated calcium channel \u03b12\u03b4 subunit in neuropathic pain","volume":"62","author":"Guo","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"105673","DOI":"10.1016\/j.neubiorev.2024.105673","article-title":"Neuropathic pain, mood, and stress-related disorders: a literature review of comorbidity and co-pathogenesis","volume":"161","author":"Vieira","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bja.2023.04.021","article-title":"Advances and challenges in neuropathic pain: a narrative review and future directions","volume":"131","author":"Attal","year":"2023","journal-title":"Br J Anaesth"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/j.pain.0000000000003239","article-title":"Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study","volume":"165","author":"Muller","year":"2024","journal-title":"Pain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the food and drug administration adverse events reporting system (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","article-title":"Gabapentin drug misuse signals: a pharmacovigilance assessment using the FDA adverse event reporting system","volume":"206","author":"Vickers-Smith","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"B9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.seizure.2021.07.011","article-title":"Severe cutaneous adverse reactions in asians: trends observed in culprit anti-seizure medicines using VigiBase\u00ae","volume":"91","author":"Shukla","year":"2021","journal-title":"Seizure"},{"key":"B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00702-024-02738-6","article-title":"Edema related to treatment with psychotropic drugs","volume":"131","author":"Engel","year":"2024","journal-title":"J Neural Transm"},{"key":"B11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2024.2448833","article-title":"Gabapentinoids related psychiatric disorders: an analysis based on the FAERS database from 2004 to 2023","volume":"25","author":"Li","year":"2026","journal-title":"Expert Opin. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/bcp.70279","article-title":"Pregabalin dependence, withdrawal, suicidality and psychosis reports: a disproportionality analysis of the Australian adverse events database","volume":"92","author":"McNeilage","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front. Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","article-title":"Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018 to 2023","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1368244","DOI":"10.3389\/fphar.2024.1368244","article-title":"A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1185\/03007995.2013.820694","article-title":"Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability","volume":"29","author":"Montgomery","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","article-title":"Pregabalin: a review of its use in adults with generalized anxiety disorder","volume":"28","author":"Frampton","year":"2014","journal-title":"CNS Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2165\/11634510-000000000-00000","article-title":"Elucidating the mechanism of action of pregabalin: \u03b12\u03b4 as a therapeutic target in anxiety","volume":"26","author":"Mic\u00f3","year":"2012","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1517\/14740338.2012.677026","article-title":"Drug safety evaluation of pregabalin","volume":"11","author":"Toth","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","article-title":"Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review","volume":"30","author":"Freynhagen","year":"2016","journal-title":"CNS Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.ajkd.2021.06.027","article-title":"Extracorporeal treatment for gabapentin and pregabalin poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"79","author":"Bouchard","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1598971","DOI":"10.3389\/fphar.2025.1598971","article-title":"Case report: synergistic central nervous system depression of baclofen and pregabalin: clinical pharmacist-driven case analysis and case review","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/bc.bc_57_19","article-title":"Pregabalin-associated movement disorders: a literature review","volume":"6","author":"Rissardo","year":"2020","journal-title":"Brain Circ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5505\/agri.2018.48753","article-title":"A probable case of pregabalin - related reversible hearing loss","volume":"32","author":"Y\u0131lmaz","year":"2020","journal-title":"Agri"},{"key":"B28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40263-022-00937-x","article-title":"Antiseizure drugs and movement disorders","volume":"36","author":"S\u00e1enz-Farret","year":"2022","journal-title":"CNS Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/jcpt.12790","article-title":"Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese adverse drug event report databases","volume":"44","author":"Mukai","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40264-025-01516-x","article-title":"Risk of fracture associated with pregabalin or mirogabalin use: a case-case-time-control study based on Japanese health insurance claims data","volume":"48","author":"Wakabayashi","year":"2025","journal-title":"Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4065\/82.1.40","article-title":"Second-generation antiepileptic drugs\u2019 impact on balance: a meta-analysis","volume":"82","author":"Sirven","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2377-12-8","article-title":"Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study","volume":"12","author":"Berger","year":"2012","journal-title":"BMC Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1097\/j.pain.0000000000001340","article-title":"Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy","volume":"159","author":"Finnerup","year":"2018","journal-title":"Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/ALN.0000000000003345","article-title":"Ketamine and magnesium for refractory neuropathic pain: a randomized, double-blind, crossover trial","volume":"133","author":"Pickering","year":"2020","journal-title":"Anesthesiology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"key":"B37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40360-024-00813-y","article-title":"Drug risks associated with sarcopenia: a real-world and GWAS study","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1806099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:40:10Z","timestamp":1790833210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1806099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1806099"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1806099","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1806099"}}